生物技术
生物制药
生化工程
风险分析(工程)
医学
工程类
生物
作者
Sergio Rosales-Mendoza,Ricardo Nieto-Gómez
标识
DOI:10.1016/j.tibtech.2018.05.010
摘要
The use of innovative platforms to produce biopharmaceuticals cheaply and deliver them through noninvasive routes could expand their social benefits. Coverage should increase as a consequence of lower cost and higher patient compliance due to painless administration. For more than two decades of research, oral therapies that rely on genetically engineered plants for the production of biopharmaceuticals have been explored to treat or prevent high-impact diseases. Recent reports on the successful oral delivery of plant-made biopharmaceuticals raise new hopes for the field. Several candidates have shown protection in animal models, and efforts to establish their production on an industrial scale are ongoing. These advances and perspectives for the field are analyzed.
科研通智能强力驱动
Strongly Powered by AbleSci AI